A prospective, randomized trial of conventional, dose-accelerated corticosteroids and intravenous immunoglobulin in children with newly diagnosed idiopathic thrombocytopenic purpura.

Authors:
  • HIH Iyori
    H Iyori
  • HOH Ohkawa
    H Ohkawa
  • SKS Konishi
    S Konishi
  • FBF Bessho
    F Bessho
  • ASA Shirahata
    A Shirahata
  • SMS Miyazaki
    S Miyazaki
  • JAJ Akatsuka
    J Akatsuka
  • JIJapanese Study Group on Childhood ITP
    Japanese Study Group on Childhood ITP

  • 1 October 2000
    • journal article
    • clinical trial
Abstract
To determine the minimal essential treatment for childhood acute idiopathic thrombocytopenic purpura (ITP), a prospective, randomized trial was conducted focusing on hemorrhagic manifestation as well as platelet count. Subjects with a platelet count of or = 10 x 10(3)/microL. Furthermore, the presence or absence of mucosal bleeding in subjects with a platelet count or = 10 x 10(3)/microL may be left untreated or may be treated with o-PSL when mucosal bleeding is evident, whereas for those with a platelet count <10 x 10(3)/microL, IVIg is the most predictable platelet enhancer. Thus, a platelet count of 10 x 10(3)/microL seems to be informative enough to decide whether to treat childhood acute ITP.